Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inovio Biomedical Corporation and Vical Incorporated are set to initiate an early stage human study of a method of delivering IL-2, an immune system stimulant, for cancer patients. The delivery system promises to significantly reduce the side effects associated with IL-2.
Subscribe to our email newsletter
Intravenous delivery of IL-2 protein is approved as a treatment for metastatic melanoma, but frequently causes severe side effects. The novel treatment approach being studied in this trial involves direct injection of IL-2 into a tumor lesion of plasmid DNA, followed by electroporation, the local application of electrical pulses designed to enhance the uptake of the protein into tumor cells.
It is hoped that this method of delivery will prove effective in attacking the tumor, but will not produce the severe side effects normally associated with IL-2.
Inovio’s president and CEO, Dr Avtar Dhillon, said, “We are pleased that Vical’s preclinical work has justified advancing this program into humans. Vical is the first of our corporate partners to initiate a clinical study using our electroporation technology to enhance delivery of a gene with potential therapeutic benefits in humans.”